4//SEC Filing
Doyle Anthony 4
Accession 0001127602-23-029831
CIK 0000882796other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:37 PM ET
Size
8.7 KB
Accession
0001127602-23-029831
Insider Transaction Report
Form 4
Doyle Anthony
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2023-12-14$6.43/sh−5,475$35,204→ 229,926 total - Award
Common Stock
2023-12-14+34,000→ 235,401 total - Award
Emp. Stock Option (Right to Buy)
2023-12-14+158,500→ 158,500 totalExercise: $6.43From: 2024-12-14Exp: 2033-12-14→ Common Stock (158,500 underlying)
Footnotes (3)
- [F1]Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- [F2]Represents shares withheld by the issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the reporting person.
- [F3]Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001808688
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:37 PM ET
- Size
- 8.7 KB